|

Comparing Antipsychotic Medications in LBD Over Time

RECRUITINGPhase 4Sponsored by The University of Texas Health Science Center at San Antonio
Actively Recruiting
PhasePhase 4
SponsorThe University of Texas Health Science Center at San Antonio
Started2022-04-22
Est. completion2026-08
Eligibility
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT05590637

Summary

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients seen in the neurology clinic at UT Health San Antonio
* Diagnosed with psychosis due to PD or DLB
* Requiring initiation of an antipsychotic medication
* Clinical equipoise between quetiapine and pimavanserin must exist
* The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin

Exclusion Criteria:

* Medical contraindication to either medication
* Caregiver unavailable to complete NPI-Q
* Currently taking an antipsychotic medication
* Prescribing provider unwilling to manage either medication

Conditions3

Dementia With Lewy BodiesParkinson's DiseaseParkinson's Disease Psychosis

Locations2 sites

University Health System
San Antonio, Texas, 78229
Sarah Horn, MD210-450-0500horns@uthscsa.edu
UT Health Science Center - San Antonio
San Antonio, Texas, 78229
Carolyn Paiz210-450-8830paizc@uthscsa.edu

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.